

# WHO Drug Information

## Contents

### General Policy Topics

Reserve antibiotics 165

### Personal Perspectives

Counterfeit medicines: a problem of today 167

### Reports on Individual Drugs.

Vasodilator therapy following myocardial infarction 169

Praziquantel: are there brand differences? 169

Progestational contraceptives: also a risk factor for breast cancer? 170

Plasma substitutes and renal failure 171

Haemopoietic growth factors as adjuvants in cancer chemotherapy 171

Haemophilia: the therapeutic dilemma 172

Calcium channel blockers: a need for reassessment? 173

Antimalarials and pruritus 174

### General Information

Should antimalarials be given to all pregnant women at risk? 175

Cost-effective health care delivery 176

Cost-conscious prescribing 176

Hazards of herbal medicines 177

Generic drug products: is interchangeability still an issue? 178

Drugs in donated blood 179

Adverse reaction reporting: engaging commitment 179

DNA probes: a new generation of diagnostic tools 180

How often are drugs really taken? 181

Asthma: inadequacies in concepts and management 181

### Regulatory Matters

Aminoglycoside antibiotics: restrictive measures 183

Aphrodisiac activity: no more claims 183

Cosmetics: disclosure of ingredients 183

Ethylene oxide: a potential carcinogen? 183

Hair restorers on prescription only 184

Mefloquine: restrictive labelling 184

Metamizole: withdrawal of combination products 184

Sulfonamides: suppository formulations withdrawn 185

L-Tryptophan supplements and eosinophilia-myalgia syndrome 185

### Advisory Notices

Delayed shock and low osmolar radiocontrast media 186

Counterfeit dermatological products 186

Counterfeit Fansidar® 186

Flunarizine and extrapyramidal symptoms 186

Minoxidil and contact dermatitis 186

Retinoids and necrotizing vasculitis 187

Steroid aerosols and cataract 187

Oral contraceptives and older women 188

Xamoterol: inappropriate for severe heart failure 188

Zidovudine: carcinogenic potential 188

Zidovudine-induced neutropenia 188

### Essential Drugs

WHO Model List: Sixth Revision 191

### Newly Registered Products 204

### Recent Publications

The role and function of the pharmacist in Europe 205

Clandestinely produced drugs, analogues and precursors 205

Naming organic compounds 205

The business of pharmaceutical inspection 206

### Proposed International Non-proprietary Names: List 62 207